Powered by analytics and modeling

Evolving marketplace dynamics, cuts in healthcare systems and governments, and the growing cost of innovation pose major challenges to demonstrating and delivering value effectively.

Powered by analytics and modeling across the entire life cycle, our commercial, HEOR, and access teams help you assess and clearly demonstrate value. We combine unmatched technical capabilities and advanced analytic methods with our deep relationships in the payer and health technology assessment (HTA) community to inform key decisions and maximize your product’s impact.

How we help our clients

Decision analytics and modeling

From early stage development through lifecycle management, we help you quantify and navigate the most difficult decisions. We are a global team of statisticians, epidemiologists and analysts with expertise in advanced predictive modeling and simulation, powered by our Health Outcomes Performance Estimator (HOPE) platform.

Health economics outcomes research

Our simple but clear and impactful HEOR framework supports your preparation for HTA and payer appraisals. It systematically addresses the key questions explored by decision makers. Our clients leverage this framework to inform early drug positioning are prepare market access strategy.

Market access and pricing

Optimize value, positioning, and evidence synthesis across all stages of the reimbursement journey. Our combination of strong science and understanding of public health decision-makers’ challenges is the key to effective market access and pricing. We assess value of health interventions with an array of methods.

Real world evidence

Drawing on decades of experience, we offer real-world data solutions for every need: from niche needs identification, justifying access, differentiating value, quantifying an opportunity to demonstrating benefit and risk. Our work is powered by real world data solutions across the entire evidence continuum.

US and EU payer engagement

Certara creates formal and informal communications with health technology assessment (HTA) and payer stakeholders, using a comprehensive and systematic framework to support HTA and payer appraisals. The result is an integrated evaluation of expected value, clear and concise briefing materials, and a strategic approach.

US managed markets

We specialize in scientific value story development, pro-active policy and payer engagement, as well as multi-faceted go-to-market and distribution strategies. We spur your success in the US Managed Markets, driving impactful science with real world evidence analytics, payer strategy, and the right commercial pull-through.

Value communication software

With Certara’s BaseCase platform, you can engage payers, providers and HCPs with interactive, data-driven content, tailored to their setting. Perform live calculations and present personalized ROI, budget impact or business case analyses. Achieve flexibility and speed with content creation and sales enablement.

Value strategy

Our teams utilize extensive experience to develop P&R strategies and commercially meaningful value arguments across a broad range of therapy areas. Our offering stands out as a unique marriage of analytics on the data in real world settings with proven payer strategy on how to best leverage that evidence for reimbursement success.
Maximizing value and access at decision points

Leveraging best-in-class capabilities in modeling & simulation, mathematics, and Bayesian statistics, we use advanced frameworks and proprietary software to:

  • Navigate the most difficult trade-off decisions
  • Inform strategic decisions for drug evaluation
  • Quantify the impact of uncertainty around outcomes based agreements
  • Removing the uncertainties between clinical trial efficacy
    and real world effectiveness
Learn more about decision analytics
Profound impact of real world data and evidence

The collection of RWD and use of RWE are having a profound impact on our industry.  Today, it is common practice for regulators to use RWE to monitor post-market safety and to make regulatory decisions. And increasingly, sponsors are leveraging RWE to support clinical trial design and observational studies to generate treatment approaches. Likewise, healthcare systems are collecting and using RWE to substantiate coverage decisions.

Our industry-leading team is focused on RWE strategies and data analysis for commercial and scientific applications.

Contact Certara
Innovative pricing and contracting to fast-track drugs

The days of simply determining the market demand as a function of price and choosing the revenue or profit optimizing point are gone.

In our new environment, the idea of an explicit rationale, also known as the “value-based price” has become a prerequisite for enabling conversation with payers while policy-makers seem poised to limit the pricing corridors with increased government intervention.

Our unique platforms help you move performance contracts beyond pilots through decision-analytics and strategic scale.

Start a conversation